[go: up one dir, main page]

ES2166110T3 - Agonistas no alostericos de gabaa para tratar trastornos del sueño. - Google Patents

Agonistas no alostericos de gabaa para tratar trastornos del sueño.

Info

Publication number
ES2166110T3
ES2166110T3 ES98102355T ES98102355T ES2166110T3 ES 2166110 T3 ES2166110 T3 ES 2166110T3 ES 98102355 T ES98102355 T ES 98102355T ES 98102355 T ES98102355 T ES 98102355T ES 2166110 T3 ES2166110 T3 ES 2166110T3
Authority
ES
Spain
Prior art keywords
sleep disorders
alosteric
gabaa
agonists
treat sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98102355T
Other languages
English (en)
Spanish (es)
Inventor
Marike Lancel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166110(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of ES2166110T3 publication Critical patent/ES2166110T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES98102355T 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño. Expired - Lifetime ES2166110T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
ES2166110T3 true ES2166110T3 (es) 2002-04-01

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
ES98102355T Expired - Lifetime ES2166110T3 (es) 1995-07-13 1996-07-10 Agonistas no alostericos de gabaa para tratar trastornos del sueño.
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.
ES98102356T Expired - Lifetime ES2166111T3 (es) 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES96925704T Expired - Lifetime ES2165990T3 (es) 1995-07-13 1996-07-10 Thip para el tratamiento de trastornos del sueño.
ES98102356T Expired - Lifetime ES2166111T3 (es) 1995-07-13 1996-07-10 Uso de tiagabina para el tratamiento de trastornos del sueño.

Country Status (12)

Country Link
US (1) US5929065A (fr)
EP (3) EP0867184B1 (fr)
JP (3) JP3754705B2 (fr)
AT (3) ATE207356T1 (fr)
AU (1) AU723954B2 (fr)
CA (1) CA2226582C (fr)
CL (1) CL2003002785A1 (fr)
DE (4) DE19525598C2 (fr)
DK (3) DK0867184T3 (fr)
ES (3) ES2166110T3 (fr)
PT (3) PT867184E (fr)
WO (1) WO1997002813A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
PT991409E (pt) * 1997-08-01 2002-06-28 Elan Corp Plc Composicoes farmaceuticas de libertacao controlada contendo tiagabina
WO2001022941A1 (fr) * 1999-09-28 2001-04-05 H. Lundbeck A/S Composition granulee par fusion et forme posologique a liberation modifiee, preparee a partir de ladite composition
PT1296671E (pt) * 2000-06-26 2008-05-09 Warner Lambert Co Substâncias análogas à gabapentina para o tratamento de perturbações do sono
EP1389091A1 (fr) * 2001-05-21 2004-02-18 H. Lundbeck A/S Preparations granulaire de gaboxadol
WO2004112786A2 (fr) 2003-06-25 2004-12-29 H. Lundbeck A/S Traitement de la depression et d'autres troubles affectifs
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005023256A1 (fr) * 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Utilisation d'agonistes des recepteurs gabaa pour traiter les troubles auditifs, vestibulaires et de l'attention, le tremblement intentionnel et le syndrome des jambes sans repos
JP5646126B2 (ja) * 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
CA2551637A1 (fr) * 2003-12-24 2005-07-14 Sepracor Inc. Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ES2337700T3 (es) * 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
JP2017516868A (ja) 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
HUE048370T2 (hu) 2015-03-24 2020-07-28 H Lundbeck As Eljárás 4,5,6,7-tetrahidroizoxazolo[5,4-c] piridin-3-ol elõállítására
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN111201022A (zh) 2017-08-04 2020-05-26 奥维德医疗公司 加波沙朵在治疗糖尿病及相关状况中的用途
WO2020061410A1 (fr) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Utilisation de gaboxadol pour le traitement du syndrome de gilles de la tourette, de tics et du bégaiement
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
EP3894028B1 (fr) 2018-12-14 2024-07-31 Raimondo Fazio Appareil d'entraînement aux arts martiaux
WO2020131856A1 (fr) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Utilisation de gaboxadol pour le traitement d'un trouble de l'alternance veille-sommeil non circadien
CN114786669A (zh) 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用
KR102773472B1 (ko) * 2021-05-21 2025-02-27 한국식품연구원 구릿대 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
CA3228780A1 (fr) * 2021-08-11 2023-02-16 Brian TANCOWNY Extraits et composes a base d'amanite tue-mouches et leur utilisation benefique et therapeutique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
AU723954B2 (en) 2000-09-07
DE19525598C2 (de) 1997-09-25
EP0840601B1 (fr) 2001-10-24
PT867184E (pt) 2002-04-29
DE69616376D1 (de) 2001-11-29
EP0867178B1 (fr) 2001-10-24
ATE207356T1 (de) 2001-11-15
JP3754705B2 (ja) 2006-03-15
ATE207352T1 (de) 2001-11-15
CA2226582A1 (fr) 1997-01-30
DK0867184T3 (da) 2002-02-18
JP2005047925A (ja) 2005-02-24
DE69616375D1 (de) 2001-11-29
JPH11509194A (ja) 1999-08-17
EP0867184B1 (fr) 2001-10-24
EP0867184A1 (fr) 1998-09-30
CA2226582C (fr) 2008-02-19
DK0840601T3 (da) 2002-02-18
DE69616376T2 (de) 2002-06-27
JP2009057382A (ja) 2009-03-19
DE69616375T2 (de) 2002-07-11
US5929065A (en) 1999-07-27
PT867178E (pt) 2002-04-29
ATE207349T1 (de) 2001-11-15
ES2165990T3 (es) 2002-04-01
PT840601E (pt) 2002-04-29
WO1997002813A1 (fr) 1997-01-30
DE69616333D1 (de) 2001-11-29
AU6613796A (en) 1997-02-10
DE19525598A1 (de) 1997-01-16
EP0867178A1 (fr) 1998-09-30
ES2166111T3 (es) 2002-04-01
DE69616333T2 (de) 2002-07-04
DK0867178T3 (da) 2002-02-18
CL2003002785A1 (es) 2005-04-08
EP0840601A1 (fr) 1998-05-13

Similar Documents

Publication Publication Date Title
ES2166110T3 (es) Agonistas no alostericos de gabaa para tratar trastornos del sueño.
EP1091745A4 (fr) Traitement de troubles hyperproliferants
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
DK0880350T3 (da) Behandling af dissemineret sklerose
EA200101089A1 (ru) Новый способ лечения
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
EA199800866A1 (ru) Способ снятия боли
BR9612552A (pt) Processo para tratamento de autismo
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
ATE236630T1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
NO970607L (no) Anordning av selegilin i behandling av epileptiske tilstander
BR9708037A (pt) Método para o tratamento de abuso de substância
BR9612549A (pt) Método para tratamento de agressão excessiva
EA199800818A1 (ru) Способ лечения бессонницы
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
PA8435601A1 (es) Composiciones farmaceuticas y metodos de tratamiento de desordenes compulsivos usando inhibidores de naaladasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 867178

Country of ref document: ES